Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment
AffiliationUNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Diseases (TDR), Geneva, Switzerland. Centre for Tropical Medicine and Vaccinology, University of Oxford, Oxford, UK. Epicentre, Paris, France. Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. Centre de Recherches Publiques (CRP)-Santé, Luxembourg.
MetadataShow full item record
AbstractOBJECTIVE: Parasites may recur asymptomatically after initial clearance by antimalarial treatment. Current guidelines recommend treatment only when patients develop symptoms or at the end of follow-up. We wanted to assess prospectively the probability of becoming symptomatic and the risks of this practice. METHODS: We analysed data collected in 13 trials of uncomplicated paediatric malaria conducted in eight sub-Saharan African countries. These studies followed all cases of post-treatment asymptomatic parasitaemia until they developed symptoms or to the end of the 28-day follow-up period, at which time parasite genotypes were compared to pre-treatment isolates to distinguish between recrudescences and new infections. RESULTS: There were 425 asymptomatic recurrences after 2576 treatments with either chloroquine, sulfadoxine/pyrimethamine or amodiaquine, of which 225 occurred by day 14 and 200 between day 15 and day 28. By day 28, 42% developed fever (median time to fever = 5 days) and 30% remained parasitaemic but afebrile, while 23% cleared their parasites (outcome unknown in 4%). Young age, parasitaemia >/=500 parasites/microl; onset of parasitaemia after day 14, and treatment with amodiaquine were the main variables associated with higher risk of developing fever. CONCLUSION: In areas of moderate to intense transmission, asymptomatic recurrences of malaria after treatment carry a substantial risk of becoming ill within a few days and should be treated as discovered. Young children are at higher risk. The higher risk carried by cases occurring in the second half of follow-up may be explained by falling residual drug levels.
- Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: up-dated baseline data from randomized and multi-site clinical trials.
- Authors: Ménard D, Ratsimbasoa A, Randrianarivelojosia M, Rabarijaona LP, Raharimalala L, Domarle O, Randrianasolo L, Randriamanantena A, Jahevitra M, Andriantsoanirina V, Rason MA, Raherinjafy R, Rakotomalala E, Tuseo L, Raveloson A
- Issue date: 2008 Apr 4
- [Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006].
- Authors: Pérez MA, Cortés LJ, Guerra AP, Knudson A, Usta C, Nicholls RS
- Issue date: 2008 Mar
- Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.
- Authors: Sutherland CJ, Laundy M, Price N, Burke M, Fivelman QL, Pasvol G, Klein JL, Chiodini PL
- Issue date: 2008 Nov 20
- Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children.
- Authors: Njama-Meya D, Kamya MR, Dorsey G
- Issue date: 2004 Aug
- Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan.
- Authors: Adam I, Elmardi KA, Malik EM
- Issue date: 2009 Jan